Diogo Maia-Silva

Diogo Maia-Silva

Auto-generated profile, based on publicly available information

Diogo Maia-Silva

Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Cell Reports
Verified
Journal Article
Open access
TSTim D.D. Somerville
Tim D.D. Somerville
YXYali Xu
Yali Xu
KMKoji Miyabayashi
Koji Miyabayashi
HTHervé Tiriac
Hervé Tiriac
CCCristian R. Cleary
Cristian R. Cleary
CVChristopher R. Vakoc
Christopher R. Vakoc
The aberrant expression of squamous lineage markers in pancreatic ductal adenocarcinoma (PDA) has been correlated with poor clinical outcomes. However, the functional role of this putative transdifferentiation event in PDA pathogenesis remains unclear. Here, we show that expression of the transcription factor TP63 (ΔNp63) is sufficient to install and sustain the enhancer landscape and transcriptional signature of the squamous lineage in human PDA cells. We also demonstrate that TP63-driven enhancer reprogramming promotes aggressive tumor phenotypes, including enhanced cell motility and invasion, and an accelerated growth of primary PDA tumors and metastases in vivo. This process ultimately leads to a powerful addiction of squamous PDA cells to continuous TP63 expression. Our study demonstrates the functional significance of squamous transdifferentiation in PDA and reveals TP63-based reprogramming as an experimental tool for investigating mechanisms and vulnerabilities linked to this aberrant cell fate transition.

8 May 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
TSTim D. D. Somerville
Tim D. D. Somerville
YXYali Xu
Yali Xu
XWXiaoli S. Wu
Xiaoli S. Wu
DMDiogo Maia-Silva
Diogo Maia-Silva
SHStella K. Hur
Stella K. Hur
CVChristopher R. Vakoc
Christopher R. Vakoc
Lineage plasticity is a prominent feature of pancreatic ductal adenocarcinoma (PDA) cells, which can occur via deregulation of lineage-specifying transcription factors. Here, we show that the zinc finger protein ZBED2 is aberrantly expressed in PDA and alters tumor cell identity in this disease. Unexpectedly, our epigenomic experiments reveal that ZBED2 is a sequence-specific transcriptional repressor of IFN-stimulated genes, which occurs through antagonism of IFN regulatory factor 1 (IRF1)-mediated transcriptional activation at cooccupied promoter elements. Consequently, ZBED2 attenuates the transcriptional output and growth arrest phenotypes downstream of IFN signaling in multiple PDA cell line models. We also found that ZBED2 is preferentially expressed in the squamous molecular subtype of human PDA, in association with inferior patient survival outcomes. Consistent with this observation, we show that ZBED2 can repress the pancreatic progenitor transcriptional program, enhance motility, and promote invasion in PDA cells. Collectively, our findings suggest that high ZBED2 expression is acquired during PDA progression to suppress the IFN response pathway and to promote lineage plasticity in this disease.

1 November 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
FCFrancisco Caiado
Francisco Caiado
DMDiogo Maia-Silva
Diogo Maia-Silva
CJCarolina Emanuel Carreira Gomes Jardim
Carolina Emanuel Carreira Gomes Jardim
NSNina Schmolka
Nina Schmolka
TCTânia Carvalho
Tânia Carvalho
BSBruno Silva-Santos
Bruno Silva-Santos
Chemotherapy-resistant cancer recurrence is a major cause of mortality. In acute myeloid leukemia (AML), chemorefractory relapses result from the complex interplay between altered genetic, epigenetic and transcriptional states in leukemic cells. Here, we develop an experimental model system using in vitro lineage tracing coupled with exome, transcriptome and in vivo functional readouts to assess the AML population dynamics and associated molecular determinants underpinning chemoresistance development. We find that combining standard chemotherapeutic regimens with low doses of DNA methyltransferase inhibitors (DNMTi, hypomethylating drugs) prevents chemoresistant relapses. Mechanistically, DNMTi suppresses the outgrowth of a pre-determined set of chemoresistant AML clones with stemness properties, instead favoring the expansion of rarer and unfit chemosensitive clones. Importantly, we confirm the capacity of DNMTi combination to suppress stemness-dependent chemoresistance development in xenotransplantation models and primary AML patient samples. Together, these results support the potential of DNMTi combination treatment to circumvent the development of chemorefractory AML relapses.

26 November 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
FCFrancisco Caiado
Francisco Caiado
DMDiogo Maia-Silva
Diogo Maia-Silva
CJCarolina Jardim
Carolina Jardim
NSNina Schmolka
Nina Schmolka
TCTânia Carvalho
Tânia Carvalho
BSBruno Silva-Santos
Bruno Silva-Santos
An amendment to this paper has been published and can be accessed via a link at the top of the paper.

15 June 2026 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
WCWilliam J. Crisler
William J. Crisler
KAKseniia S. Anufrieva
Kseniia S. Anufrieva
MWMaureen Whittelsey
Maureen Whittelsey
AMArjun Mahajan
Arjun Mahajan
DMDiogo Maia-Silva
Diogo Maia-Silva
ALAvery LaChance
Avery LaChance